scispace - formally typeset
E

Eric B. Durbin

Researcher at University of Kentucky

Publications -  64
Citations -  1054

Eric B. Durbin is an academic researcher from University of Kentucky. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 12, co-authored 50 publications receiving 541 citations. Previous affiliations of Eric B. Durbin include Markey Cancer Center.

Papers
More filters
Journal ArticleDOI

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

Petros Grivas, +128 more
- 01 Jun 2021 - 
TL;DR: In this article, the authors analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Journal ArticleDOI

Incidence of brain metastasis at initial presentation of lung cancer

TL;DR: The authors' analysis from the Kentucky and Alberta cancer registries similarly demonstrated the aggressive nature of lung cancer and its propensity for BM at initial presentation, and no synchronous organ site predicted BM in lung cancer.
Journal ArticleDOI

Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study

TL;DR: An exploratory, observational cohort study assesses the effect of α1-blocker exposure on the incidence of prostate cancer through the induction of apoptosis and decrease in tissue vascularity.
Journal ArticleDOI

Limitations of Transformers on Clinical Text Classification

TL;DR: In this article, the authors introduce four methods to scale BERT, which by default can only handle input sequences up to approximately 400 words long, to perform document classification on clinical texts several thousand words long.
Journal ArticleDOI

Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma

TL;DR: A multivariable model, incorporating patient age, glioblastoma multiforme diagnosis, and prior history of grade II or III glioma, was developed to predict IDH1/2 mutation probability and can help triage diffuse gliomas that would benefit from mutation testing in both clinical and research settings.